Expression of PD-L1 and infiltration of cytotoxic T lymphocytes (CTLs) in tumor microenvironments are reported to be the prerequisite for effective response of PD-L1 pathway blockade therapy in many cancer patients (Ock et al., 2016; Teng et al., 2015). This evidence concerns the gene CD274 and cancer.